This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The economic analysis included the costs of screening tests, pelvic examination, cervicitis treatment visit, medication for cervicitis, in-patient and out-patient PID treatment, and other treatments for infertility, ectopic pregnancy, and chronic pelvic pain. These costs were based on Medicare reimbursement rates, the literature, and the Health Care Utilization Project. Little information about resource use was provided. It was stated that the time required to perform a speculum examination was based on a time-in-motion study. All costs were in US dollars ($) and the price year was 2006. Future costs were discounted at 3% per annum. Cost-to-charge ratios were applied, when only charge data were available.
Analysis of uncertainty:
One-and two-way sensitivity analyses were carried out on the model inputs, using ranges of values based on published evidence or primary data. The cost-effectiveness threshold was set at $400 per PID case prevented, by the consensus of experts.
Results
In the whole cohort, the total costs were $636,913 with endocervical DNA probe; $627,204 with endocervical AC2; $613,732 with urine AC2; and $573,205 with self-obtained vaginal AC2. The expected PID cases were 115 with endocervical DNA probe; 44 with endocervical AC2; 44 with urine AC2; and 27 with self-obtained vaginal AC2. Thus, endocervical DNA probe was dominated, as all the other strategies were cheaper and prevented more PID cases. The dominant strategy (cheaper and more effective than the other strategies) was self-obtained vaginal AC2.
In general, the base-case results were stable to variations in the model inputs, including disease prevalence, but the size of the savings associated with self-obtained vaginal AC2 changed depending on the parameter varied. Self-obtained vaginal AC2 was no longer dominant, when the sensitivity of urine AC2 was assumed to be higher than that of selfobtained vaginal AC2, or when the sensitivity of endocervical AC2 was set at 99%.
